Souhaitez-vous accéder aux communiqués récents ?

Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Self-Monitoring Blood Glucose (Smbg) Devices Market Outlook 2025-2034: Market Share, and Growth Analysis" report has been added to ...

The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A...

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”)...

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Japan Insulin Pen Market Growth Outlook 2025-2033" has been added to ResearchAndMarkets.com's offering.The Japan Insulin Pen Market is forecasted to...

Dublin, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The "United States Insulin Pump Market Outlook 2025-2033" report has been added to ResearchAndMarkets.com's offering.The United States Insulin Pump Market...

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Self-monitoring Blood Glucose Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been...

Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Continuous Glucose Monitoring (CGM) Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Continuous...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given...

Inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications.